INTRODUCTION

Due to the increased uptake of rectal cancer screening and the increasing rates of complete clinical response to chemoradiotherapy, more early-stage and down-staged rectal cancers are being treated. This has triggered surgeons to question the necessity for proctectomy and its associated morbidity and consider local excision and organ preservation in selected cases. Transanal minimally invasive surgery (TAMIS) has evolved as an oncologically safe yet cost-effective platform for local excision of rectal tumors using traditional laparoscopic instruments. This review highlights the recent advances and current role of TAMIS in the treatment of rectal cancer.

Abstract
Due to the increased uptake of rectal cancer screening and the increasing rates of complete clinical response to chemoradiotherapy, more early-stage and down-staged rectal cancers are being treated. This has triggered surgeons to question the necessity for proctectomy and its associated morbidity and consider local excision and organ preservation in selected cases. Transanal minimally invasive surgery (TAMIS) has evolved as an oncologically safe yet cost-effective platform for local excision of rectal tumors using traditional laparoscopic instruments. This review highlights the recent advances and current role of TAMIS in the treatment of rectal cancer.

KEYWORDS
rectal cancer, TAMIS, transanal minimally invasive surgery

1 Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland
2 AdventHealth Colorectal Surgery, Orlando, FL, USA

Correspondence
Matthew R. Albert, AdventHealth Cancer Institute, 2501 North Orange Ave, Orlando, FL 32804, USA.
Email: matthew.albert.md@adventhealth.com

Transanal excision utilizes traditional open surgery instruments under direct vision. Exposure is limited for all but the most distal rectal lesions and rates of specimen fragmentation as well as margin positivity are high.6

Transanal endoscopic microsurgery, first described in 1984,7 uses a fixed rigid resectoscope and insufflation to maintain pneu- morectum and provide a stable digital or binocular magnified view. Proprietary instruments are then used to operate through the two working ports. When compared to conventional TAE, TEM provides a superior quality resection, with higher rates of negative microscopic margins, reduced rates of specimen fragmentation, and lesion recurrence but with equivalent postoperative complications.8 When compared to advanced colonoscopic techniques such as endoscopic mucosal resection and endoscopic submucosal dissection, TEM re- mains superior with respect to lesion recurrence.9,10

However, while TEM has been used for more than 30 years, it has been slow to become incorporated into routine colorectal prac- tice due to a steep learning curve11 and significant associated initial cost of the operating system.12 These limitations and the need for an oncologically safe and also cost-effective procedure led to evolution of TAMIS.
Transanal minimally invasive surgery utilizes conventional laparoscopic instruments and cameras with a single incision port rather than a specialized platform. This lowers the cost of the procedure and enables the surgeon to operate with familiar instruments. Another advantage is that TAMIS obtains a 360° exposure of the rectal lumen which allows operating in multiple quadrants using the same configuration, while TEM requires repositioning of the patient or the platform. First described in 2010, TAMIS was found to be a feasible alternative to TEM, providing its benefits at a fraction of the cost without specialized instrumentation.

The most common indications for TAMIS are for benign and malignant rectal tumors. However since its inception, it has been used in a wide variety of clinical scenarios from rectal prolapse and fistula repair to managing anastomotic complications and foreign body retrieval. TAMIS has also evolved to become a platform for transanal total mesorectal excision (taTME).

This chapter reviews the current and future role of TAMIS in the local treatment of rectal cancer.

## 2 | INDICATIONS FOR LOCAL EXCISION OF RECTAL CANCER

### 2.1 | T1N0M0 rectal cancer

In Japan, the United States, and Europe, en bloc full-thickness local excision is indicated for T1N0 rectal cancers with low-risk pathologic features.

The main concern regarding local excision is the potential under-treatment of T1 cancers that are node positive. Data from the Swedish Rectal Cancer Registry of 205 T1 rectal cancers demonstrated the overall rate of nodal metastasis was 12%20; however, if no adverse features were present, the rate was 6%.20

A meta-analysis of 4510 patients highlighted the risk factors for nodal metastasis in the setting of T1 rectal cancer to include submucosal invasion >1 mm (odds ratio [OR]: 3.87), lymphovascular invasion (OR: 4.81), poor differentiation (OR: 5.60), and tumor budding (OR: 7.74).21 If any of these risk factors are present on final pathology, radical proctectomy is recommended in fit patients due to the higher risk of lymph node metastasis.

Analysis of the United States Surveillance, Epidemiology, and End Results demonstrated that local excision of T1 rectal cancer does not affect cancer-specific survival when compared to radical surgery.22

### 2.2 | T2N0M0 rectal cancer

The risk of positive lymph nodes in T2 cancers is approximately 22%20 and these patients should be recommended to undergo traditional total mesorectal excision unless enrolled in a clinical trial as local excision is still deemed somewhat experimental.23 However, promising results have been published for local excision of selected T2 cancers following neoadjuvant therapy.24,25

A randomized trial of local excision vs TME for T2N0 low rectal cancers following neoadjuvant chemoradiotherapy showed that recurrence and survival were similar between groups at over 9 years of follow-up.25 The ACOSOG Z6041 study of 79 patients with T2N0 cancers treated with neoadjuvant chemoradiotherapy reported a low local recurrence rate of 4% after a median of 56 months as well as a 3 year disease-free survival of 88%.2 A retrospective analysis of the National Cancer Database in the United States also showed that, for patients with T2N0 cancers, there was no difference in overall survival between radical surgery and chemoradiotherapy followed by local excision.24

However, for some patients, pelvic radiotherapy and/or chemoradiotherapy can cause morbidity or functional impairment that is comparable to that associated with radical surgery.1 Currently, neoadjuvant radiotherapy for clinical stage T1N0 or T2N0 patients is not standard practice and can be avoided if these patients are treated with upfront curative TME.

### 2.3 | Local excision after neoadjuvant chemoradiotherapy

Five year results from the GRECCAR 2 study show no difference in oncological outcomes between local excision and total mesorectal excision for selected rectal cancers that respond well to neoadjuvant chemoradiotherapy.4 This study included patients with T2-T3 and N0–N1 rectal cancers, ≤8 cm from the anal verge and ≤4 cm in diameter. Randomization occurred if patients had a good clinical response defined as residual tumor ≤2 cm at 8 weeks postradiotherapy. Patients undergoing local excision were planned for completion TME if the specimen pathology showed ≥T2 or R1 disease. Completion TME did not significantly affect oncologic outcomes compared with patients with ≥T2 disease treated with initial TME.

The reported pathologic complete response rate following neoadjuvant chemoradiotherapy for rectal cancer is over 20%;26 however, this poorly correlates with clinical complete response as the majority of patients with a clinical complete response have residual cancer on pathology.27 If organ preservation is being pursued following a complete clinical response, there is debate whether to excise the scar or “watch and wait.” Local excision can determine if there are residual viable tumor cells giving prognostic information and selecting patients who may benefit from TME; however, local excision after chemoradiotherapy can negatively affect anorectal function.28

Tumor regrowth after a clinical complete response is reported as ≥20%29 and most can safely undergo salvage surgery.30 In the GRECCAR 2 study, tumor regrowth was only 7% after 5 years in the local excision group, albeit those with ≥T2 or R1 disease underwent completion TME.4 Of the 81 patients treated with local excision in the pre-treatment analysis, 38 (47%) had indications for completion TME with 28 (35%) undergoing TME. The high rate of organ
preservation and excellent oncologic results in this study are promising as the GRECCAR 2 cohort included patients with a good response and not just a complete clinical response.

2.4 | Advanced disease

Local excision with TAMIS may be considered for more advanced disease as a less invasive but oncologically inferior alternative to radical excision in patients with prohibitive comorbidities or who refuse radical surgery. Non-surgical treatment options such as palliative chemoradiotherapy should be considered, especially for \( \text{T}2 \) disease due to the high risk of local recurrence and symptoms. In the palliative setting, treatment plans should be tailored to consider patient symptoms, comorbidities, expected survival, and tumor stage.

2.5 | Preoperative staging

A full physical examination, including rigid proctoscopy and digital rectal exam should be performed by the operating surgeon to determine the distance of the lesion from the anal verge in centimeters, mobility, size, percentage of circumference involvement, anterior or posterior location, its position in relation to the sphincter complex and to the valves of Houston. As with any rectal lesion, all patients should undergo a full colonoscopy to rule out any synchronous pathology. While this text discusses TAMIS for rectal cancer, approximately 18.8% of transanally resected clinically benign adenoma will have invasive adenocarcinoma on their final pathology. Non-surgical treatment options such as palliative chemoradiotherapy should be considered, especially for >T2 disease due to the high risk of local recurrence and symptoms. In the palliative setting, treatment plans should be tailored to consider patient symptoms, comorbidities, expected survival, and tumor stage.

2.6 | Tamis technique

Mechanical bowel preparation should be administered preoperatively, and prophylactic antibiotics given. Following informed consent, patients should be administered general anesthesia; however, spinal anesthesia may be considered in high-risk patients. Positioning in the high dorsal lithotomy allows access to lesions in any location. Following antisepctic skin preparation and draping, the transanal port is inserted and sutured in place (Figure 1). Pneumorectum is established using \( \text{CO}_2 \) insufflation with a flow rate of 40 mm Hg/min and a pressure of 15 mm Hg. The Airseal insufflator (Airseal™, Surgiquest) can improve pneumorectum stability at lower pressures, even during use of suction, in addition to dramatically reducing intraluminal smoke. A 5 mm, 30° or 45° camera provides optimal visualization and working space in the tight confines of the rectum compared with 10 mm or 0° cameras. Image stabilization and sufficient visualization of the working space is dependent on an experienced assistant surgeon.

A premium should be placed on the surgical technique and quality of resection; a non-fragmented specimen with negative margins has repeatedly demonstrated the lowest risk of recurrence. A 10 mm margin is first scored out on the mucosa using electrocautery to maintain orientation and mark the resection (Figure 2A). Standard monopolar electrocautery with a spatula, pinpoint, or L-hook cautery allows precise dissection of the tumor and is cheap and reusable. Energy devices can also be used with the principal advantage of hemostasis, albeit with increased costs. Most practitioners utilize standard, straight non-articulating laparoscopic instruments. Handling of the tumor or polyp with graspers should be avoided and reduced to the surrounding mucosa to limit specimen fragmentation. For malignant lesions, a full-thickness excision must be performed with the objective of obtaining a 1 cm minimum negative margin. Stage I rectal cancers rarely have intramural or mesenteric spread (2.7%) and if this occurs the maximum extent is 4 mm. In contrast
to the historical description of a simple full-thickness incision into perirectal fat, we support a pyramidal, volumetric excision containing an adequate specimen of perirectal fat (Figure 2B). This assures an adequate resection with negative margins, in addition to potentially retrieving surrounding lymph nodes for pathologic sampling. Aggressive mesorectal excision should not breach the mesorectal fascia as it will make future total mesorectal excision challenging, if it is required.

Specimen extraction should be performed at completion of resection and prior to defect closure to maintain specimen integrity and avoid accidental proximal migration. The majority of platforms accommodate this by allowing removal of the faceplate; however, some ports require removal of the entire device with reinsertion for closure. Irrigation of the excision bed with dilute betadine or chlorhexidine, presumably for its tumoricidal and bactericidal effects, is a common practice; however, no evidence-based literature exists to support this. The specimen should be pinned and orientated to ensure accurate pathologic assessment (Figure 3).

Rectal wall or mucosal defects are closed in a full-thickness manner with absorbable suture material (Figure 2C). The use of a V-Loc™ suture (Covidien) can facilitate continuous closure by maintaining tension and negating the need for knot-tying. Conversely, closure can be performed in an interrupted fashion with knot-tying facilitated by disposable devices such as the CorKnot® System (LSI Solutions) or by laparoscopic knot pushers. The use of modern suturing devices can significantly shorten the learning curve at the expense of increased procedural costs. Specialized silver beads with applicators initially designed for use with the TEM system are frequently used; however, several other simpler laparoscopic knot-tying devices and methods have since become available. Whether the defect should be closed or left open remains an issue of debate. Surgeons advocating closure, site expedited healing, less bleeding, and diminished risk of stricture. Conversely, other practitioners believe it to be solely aesthetic, increasing operative time without any improvement in healing. A series of 75 patients with 1 year of follow-up after undergoing TAMIS resection has demonstrated no difference between groups.38

3 | OPERATIVE OUTCOMES

3.1 | Complications

The complications attributable to TAMIS reported in the literature to date have been minor, the commonest being post-procedural hemorrhage, which can occur early postoperatively or be delayed in presentation.39,40-42 Cases of post-procedural hemorrhage that
do not stop spontaneously have in all cases been managed successfully either endoscopically or with examination under anesthesia and over-sewing. Scrotal emphysema appears to resolve spontaneously.39 Transient pyrexia responds to oral antibiotic treatment40 and urinary retention resolved following urethral catheterization.41

Serious consideration must be given to the risk of inadvertent or unplanned intraoperative entry and its recognition is imperative.39 This is more likely to happen during the resection of larger lesions, with an anterior location, with an uppermost level over 10 cm from the anal verge.42 The largest TAMIS series published to date report a 2% incidence of perioperative entry.39 The management of this complication must be individualized depending on the size of the defect and the patient. These defects may be repaired either transanally or with a combined abdominal approach. The decision to fashion a subsequent diverting ostomy must also be individualized to the patient and their ability to tolerate a subsequent anastomotic leak with reported incidence of diverting ostomy in the setting of TEM being 0%–14%.42,43

3.2 | Oncologic quality

Being a relatively new and novel surgical modality, there is limited short-term oncological follow-up for TAMIS excisions. These were discussed in a recent systematic review that included 259 patients and specifically addressed the rates of recurrence of benign and malignant rectal neoplasms after TAMIS surgery.44 Altogether, there were 2.7% incidence of recurrence reported with 7.1-month mean follow-up. A review of TAMIS outcomes demonstrates that more than 60% of surgeons consistently performed full-thickness excision while 10% performed only submucosal excisions. Thirty percent of surgeons performed both full thickness excisions and submucosal excisions depending on the location of tumor and pathology.

3.3 | Functional/anorectal physiology

A recent series of 25 patients undergoing TAMIS with a SILS™ port assessed at 3 months following surgery with a combination of anorectal ultrasonography and a fecal incontinence severity index (FISI) score did not show anal sphincter injury or fecal incontinence-related symptoms, respectively.35 A further series of 37 patients undergoing TAMIS revealed an improvement in FISI score for patients with impaired preoperative continence.45 Conversely, analysis of anorectal function following TEM has shown at 3 months following excision, the mean Wexner continence score deteriorates, with associated symptoms of fecal urgency, but returns to baseline within 5 years.46 Post-operative manometry values at 3 months are significantly lower than at baseline but return to preoperative values at 1 year.46,47 Thus, there has been no demonstration to date that the performance of TAMIS adversely affects patient continence.

4 | FOLLOW-UP

Pathologic analysis should take place at a multidisciplinary team meeting and, for early T1 cancers, national guidelines should be followed. The National Comprehensive Cancer Network recommend a history, physical examination, rigid proctoscopy, and serum CEA level should be performed every 3 months for 2 years, then every 6 months for a total of 5 years. A full colonoscopy at 1 and 3 years following resection should be performed and every 5 years thereafter to identify metachronous lesions. It is the authors’ practice to further perform an MRI of the pelvis to identify suspicious lymph nodes every 6 months for the first 2 years following resection of early T1 cancers.

If the tumor is a high-risk T1 or more advanced lesion, a discussion may take place regarding completion TME unless the patient is enrolled in a clinical trial or there are other factors precluding them from further surgery.

5 | FUTURE DIRECTION

A number of ongoing trials are assessing the outcomes of local excision of rectal cancer in combination with chemoradiotherapy and as such the role of TAMIS in rectal cancer treatment may expand.

Following local excision in high-risk T1 and low-risk T2 rectal cancers, the outcome of completion TME vs adjuvant chemoradiotherapy is under investigation in the TESAR Dutch trial.48 The GRECCARI2 study is investigating the role of neoadjuvant FOLFIRINOX in addition to radiochemotherapy for T2/T3 N0/N1 rectal cancer to determine if this can increase the rate of organ preservation. All good responders will undergo local excision to histologically assess if TME is indicated.49 STAR-TREK is designed as a three-arm trial of TME vs watch and wait vs local excision for T1–T3b N0 rectal cancer following either long-course chemoradiotherapy or short-course radiotherapy.

Advances in TAMIS technique may be possible with robotic platforms which have the potential to improve ergonomics in the confined space of a transanal approach. Early reports have shown robotic-TAMIS to have similar short-term outcomes but at a higher cost.51 Other innovations which may improve this technique are real-time intraoperative assessment of tissue and margins with mass spectrometry52 or immunofluorescence.53

6 | CONCLUSIONS

Based on current evidence, TAMIS, in experienced hands, results in the high-quality local excision of early rectal cancers with low rates of margin positivity and low recurrence rates. TAMIS has an excellent morbidity profile with no long-term adverse effect on continence.

The role of TAMIS in treating more advanced rectal cancer remains the subject of ongoing trials. As such, the authors recommend that for tumors that are high-risk T1 or more advanced, a discussion
should take place regarding completion TME. TAMIS can also be considered as a palliative procedure to patients with metastatic disease, which would potentially avoid complications of a major surgery.

Transanal minimally invasive surgery has enabled the performance of high-quality local excision of rectal lesions by many colorectal surgeons, integrating transanal endoscopic surgery into mainstream practice. As with all new surgical techniques, appropriate training must be ensured, and the continued assessment and assurance of oncological outcome must be maintained.

DISCLOSURE

Funding: There was no funding provided for this submission.

Conflict of interests: Author MA is a consultant for, and receives honorarium for education/courses from, Applied Medical, Stryker Endoscopy, and Conmed. MA is a consultant and advisory board member for Proximie. MA is a consultant and receives financial support for research from Astellas. MA is a consultant for Cooper Surgical.

Author contribution: Liam Devane performed initial manuscript, editing and final manuscript. John Burke and Justin Kelly performed initial manuscript structure, editing, and final proofing. Matthew Albert performed editing, illustrations/photos and final proofing.

ORCID
Liam A. Devane https://orcid.org/0000-0002-7562-5780

REFERENCES

1. Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol. 2010;28(27):4233–9.

2. Peeters K, van de Velde C, Leer J, Martijn H, Junggeburt J, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206.

3. Zhou X, Wang B, Li F, Wang J, Fu W. Risk factors associated with recurrence in early colorectal cancer. Int J Clin Oncol. 2016;21(2):370–5.

4. van der Wee RN, van der Heijden LM, van den Broek F, van der Heijst IM, de Groot AM, van der Vorst JP, et al. Prognostic factors for colorectal cancer in patients with a high recurrence rate. J Clin Oncol. 2010;28(13):2199–206.

5. García-Aguilar J, Renfrö LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465–76.

6. Garcia-Aguilar J, Renfrö LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):463–76.

7. Garcia-Aguilar J, Renfrö LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465–76.

8. Clancy C, Burke JP, Albert MR, O’Connell PR, Winter DC. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. Dis Colon Rectum. 2015;58(2):254–61.

9. Barendse R, van den Broek F, Dekker E, Bemelman W, de Graaf E, Fockens P, et al. Systematic review of endoscopic mucosal resection versus transanal endoscopic microsurgery for large rectal adenomas. Endoscopy. 2011;43(11):941–9.

10. Arezzo A, Passera R, Saito Y, Sakamoto T, Kobayashi N, Sakamoto N, et al. Systematic review and meta-analysis of endoscopic submucosal dissection versus transanal endoscopic microsurgery for large non-invasive rectal lesions. Surg Endosc. 2014;28(2):427–38.

11. Barendse RM, Dijkstra MG, Rolf UR, Bijnen AB, Consten ECJ, Hoff C, et al. Colorectal surgeons’ learning curve of transanal endoscopic microsurgery. Surg Endosc. 2013;27(10):3591–602.

12. Maslekar S, Pillinger SH, Sharma A, Taylor A, Monson J. Cost analysis of transanal endoscopic microsurgery for rectal tumours. Colorectal Dis. 2007;9(3):229–34.

13. Atallah S, Albert M, Larach S. Transanal minimally invasive surgery: a giant leap forward. Surg Endosc. 2010;24(9):2200–5.

14. Melin AA, Kalaskar S, Johnson BS, Turrent C, Langenfeld SJ. Transanal endoscopic microsurgery and transanal minimally invasive surgery: is one technique superior? Am J Surg. 2016;212(6):1063–7.

15. Keller DS. Applications beyond local excision. In: Atallah S, editor. Transanal minimally invasive surgery (TAMIS) and transanal total mesorectal excision (taTME): a stepwise description of the surgical technique with video demonstration. Tech Coloproctol. 2013;17(3):321–5.

16. Hashiguchi Y, Muro K, Saito Y, Ito Y, Aioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.

17. Monson JRT, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2013;56(5):535–50.

18. Clayman RL. Transurethral surgery for bladder neck obstruction: an evolution of technique. World J Urol. 2010;28(6):567–73.

19. Gleave ME, Reddy SM. Surgical treatment of T2N0 rectal cancer: a national cancer database analysis. J Gastrointest Surg. 2017;21(10):1666–74.

20. Lezoche E, Baldarelli M, Lezoche G, Pagani MI, Gesuita R, Guerrieri M. Randomized clinical trial of endoluminal locoregional...
resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg. 2012;99(9):1211–8.

26. Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2016;23(4):1177–86.

27. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194(2):131–5; discussion 5–6.

28. Habr-Gama A, Lynn PB, Jorge JMN, São Julião GP, Proscurshim I, Serra-Aracil X, Caro-Tarrago A, Mora-Lopez L, Casalots A, Rebasa P, Tyc-Szczepaniak D, Wyrwicz L, Kepka L, Michalski W, Olszyna-Kopeć E, Dattani M, Heald RJ, Goussous G, Broadhurst J, São Julião GP, Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(12):825–36.

29. Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum. 2016;59(4):264–9.

30. Dattani M, Heald RJ, Goussous G, Broadhurst J, São Julião GP, Habr-Gama A, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268(6):955–67.

31. Tyc-Szczepaniak D, Wyrwicz L, Kepka L, Michalski W, Olszyna-Seremeta M, Palucki J, et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol. 2013;24(11):2829–34.

32. Serra-Aracil X, Caro-Tarrago A, Mora-Lopez L, Casalots A, Rebasà P, Navarro-Soto S. Transanal endoscopic surgery with total wall excision is required with rectal adenomas due to the high frequency of adenocarcinoma. Dis Colon Rectum. 2014;57(7):823–9.

33. Lee L, Arbel L, Albert MR, Atallah SB, Hill J, Monson JRT. Radiologic evaluation of clinically benign rectal neoplasms may not be necessary before local excision. Dis Colon Rectum. 2018;61(10):1163–9.

34. Fernández-Esparrach G, Ayuso-Colella JR, Sendino O, Pagés M, Cuatrecasas M, Pellisé M, et al. Palliative radiotherapy and chemotherapy after surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol. 2013;24(11):2829–34.

35. Lee SG, Russ AJ, Casillas MA Jr. Laparoscopic transanal minimally invasive surgery (LT-MIS) versus robotic TAMIS (R-TAMIS): short-term outcomes and costs of a comparative study. Surg Endosc. 2017;31(12):4926–33.

36. Bislenghi G, Wolthuis AM, de Buck van Overstraeten A, D’Hoore W, Lee TG, Lee SJ. Transanal single-port microsurgery for rectal tumours: minimal invasive surgery under spinal anesthesia. Surg Endosc. 2014;28(1):271–80.

37. Bislenghi G, Wolthuis AM, de Buck van Overstraeten A, D’Hoore W. AirSeal system insufflator to maintain a stable pneumorectum during TAMIS. Tech Coloproctol. 2015;19(1):43–5.

38. Shimada Y, Takii Y, Maruyama S, Ohta T. Intramural and mesorectal distal spread detected by whole-mount sections in the determination of optimal distal resection margin in patients undergoing surgery for rectosigmoid or rectal cancer without preoperative therapy. Dis Colon Rectum. 2011;54(12):1510–20.

39. Hahnloser D, Cantero R, Salgado G, Dindo D, Rega D, Delrio P. Transanal minimal invasive surgery for rectal lesions: should the defect be closed? Colorectal Dis. 2015;17(5):397–402.

40. Albert MR, Atallah SB, deBeche-Adams TC, Izfar S, Larach SW. Transanal minimally invasive surgery (TAMIS) for local excision of benign neoplasms and early-stage rectal cancer: efficacy and outcomes in the first 50 patients. Dis Colon Rectum. 2013;56(3):301–7.

41. Gorgun IE, Aytaç E, Costedio MM, Erem HH, Valente MA, Stocchi L. Transanal endoscopic surgery using a single access port: a practical tool in the surgeon’s toybox. Surg Endosc. 2014;28(5):1034–8.

42. Hompes R, Ris F, Cunningham C, Mortensen NJ, Cahill RA. Transanal glove port is a safe and cost-effective alternative for transanal endoscopic microsurgery. Br J Surg. 2012;99(10):1249–35.

43. Marks JH, Frenkel J, Greenleaf CE, D’Andrea AP. Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe? Dis Colon Rectum. 2014;57(10):1176–82.

44. Eyvazadeh DJ, Lee JT, Madoff RD, Mellgren AF, Finne CO. Outcomes after transanal endoscopic microsurgery with intraperitoneal anastomosis. Dis Colon Rectum. 2014;57(4):438–41.

45. Martin-Perez B, Andrade-Ribeiro GD, Hunter L, Atallah S. A systematic review of transanal minimally invasive surgery (TAMIS) from 2010 to 2013. Tech Coloproctol. 2014;18(9):775–88.

46. Schiphorst AH, Langenhoff BS, Maring J, Prönk A, Zimmerman DD. Transanal minimally invasive surgery: initial experience and short-term functional results. Dis Colon Rectum. 2014;57(8):927–32.

47. Alliax ME, Rebècchi F, Giaccone C, Mistrangelo M, Morino M. Long-term functional results and quality of life after transanal endoscopic microsurgery. Br J Surg. 2011;98(11):1635–43.

48. Kreis ME, Jehle EC, Haug V, Manncke K, Bues GF, Becker HD, et al. Functional results after transanal endoscopic microsurgery. Dis Colon Rectum. 1996;39(10):1116–21.

49. Borstlap WAA, Tanis PJ, Koedam TWA, Marijnen CAM, Cunningham C, Dekker E, et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer. 2016;16:913.

50. Optimisation of Response for Organ Preservation in Rectal Cancer: Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy. [cited Aug 3, 2015]. Available from https://ClinicalTrials.gov/show/NCT02514278

51. Rombouts AJM, Al-Najami I, Abbott NL, Appelt A, Baatrup G, Bach RA. Visual probing of rectal neoplasia: near-infrared interrogation of clinically benign rectal neoplasms and early-stage rectal cancer. BMC Cancer. 2016;16:913.

52. Mason S, Manoli E, Poynter L, Alexander J, Paizs P, Adebesin A, et al. Can we Save the rectum by watchful waiting or TransAnal Microsurgery (MS-TAMIS) to promote organ preservation in rectal cancer? A pilot study? BMJ Open. 2017;7(12):e019474.

53. Lee SG, Russ AJ, Casillas MA Jr. Laparoscopic transanal minimally invasive surgery (LT-TAMIS) versus robotic TAMIS (R-TAMIS): short-term outcomes and costs of a comparative study. Surg Endosc. 2019;33(6):1981–7.

54. Mason S, Manoli E, Poynter L, Alexander J, Paizs P, Adebisin A, et al. Mass spectrometry transanal minimally invasive surgery (MS-TAMIS) to promote organ preservation in rectal cancer. Surg Endosc. 2020;34(8):3618–25.

55. Khokhar HA, Loughman E, Khogali M, Mulligan N, O’Shea DF, Cahill RA. Visual probing of rectal neoplasia: near-infrared interrogation of primary tumors and secondary lymph nodes. Minerva Chir. 2018;73(2):217–26.

How to cite this article: Devane LA, Burke JP, Kelly JJ, Albert MR. Transanal minimally invasive surgery for rectal cancer. Ann. Gastroenterol. Surg. 2021;5:39–45. doi:10.1002/ags3.12402